Global N Sulphoglucosamine Sulphohydrolase Pipeline Review 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016" report to their offering.

N Sulphoglucosamine Sulphohydrolase pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

N Sulphoglucosamine Sulphohydrolase N-sulphoglucosamine sulphohydrolase is an enzyme encoded by the SGSH gene. This enzyme is involved in the lysosomal degradation of heparan sulfate. Mutations in this gene are associated with Sanfilippo syndrome A, one type of the lysosomal storage disease mucopolysaccaridosis III.

The report 'N Sulphoglucosamine Sulphohydrolase - Pipeline Review, H2 2016' outlays comprehensive information on the targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies

Universities.

It also reviews key players involved in N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II and Preclinical stages are 5 and 1 respectively.

Key Topics Covered:

1. Introduction
2. N Sulphoglucosamine Sulphohydrolase Overview
3. Therapeutics Development
4. Pipeline Products for N Sulphoglucosamine Sulphohydrolase - Overview
5. Pipeline Products for N Sulphoglucosamine Sulphohydrolase - Comparative Analysis
6. N Sulphoglucosamine Sulphohydrolase - Therapeutics under Development by Companies
7. N Sulphoglucosamine Sulphohydrolase - Therapeutics under Investigation by Universities/Institutes
8. N Sulphoglucosamine Sulphohydrolase Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. N Sulphoglucosamine Sulphohydrolase - Products under Development by Companies
13. N Sulphoglucosamine Sulphohydrolase - Products under Investigation by Universities/Institutes
14. N Sulphoglucosamine Sulphohydrolase - Companies Involved in Therapeutics Development

• Abeona Therapeutics, Inc.
• ArmaGen Inc.
• Laboratorios Del Dr. Esteve S.A.
• Lysogene
• Shire Plc

For more information about this report visit http://www.researchandmarkets.com/research/284zz8/n